Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Adds To Diabetes Franchise With SmartCells Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck announced Dec.2 that it is acquiring privately-held SmartCells for the company's preclinical SmartInsulin diabetes program in a deal potentially worth as much as $500 million. The acquisition will help bolster sales of Merck's blockbuster diabetes drug Januvia.

You may also be interested in...



Novo Nordisk Makes Long-Term Bet On GBM Technology With Ziylo Buy

Novo Nordisk has bought UK-based start-up Ziylo in hopes of accelerating development of glucose-responsive insulins, but admits any such products are at least ten years away.

Taking Wing With Biotech Angel Investors

They’re not just for seed rounds anymore: in the life sciences, rich individuals are supplying more early stage capital than ever, occasionally well past the Series A stage, and some are banding together into groups that look increasingly like traditional venture capital. How far will this phenomenon fly?

Merck-Geisinger Collaboration Aims For “Pipeline” Of Treatment Adherence Tools

The first tool that will be developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome.

Related Content

Topics

UsernamePublicRestriction

Register

PS071558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel